Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer

被引:10
|
作者
Gupta, Swati [1 ]
Mani, Navin R. [1 ]
Carvajal-Hausdorf, Daniel E. [1 ,2 ]
Bossuyt, Veerle [1 ]
Ho, Kenneth [3 ]
Weidler, Jodi [4 ]
Wong, Wendy [3 ]
Rhees, Brian [3 ]
Bates, Michael [4 ]
Rimm, David L. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ Desarrollo, Fac Med, Clin Alemana, Anat Patol, Santiago, Chile
[3] Cepheid, Div Oncol Res & Dev, Oncol, Sunnyvale, CA USA
[4] Cepheid, Med & Sci Affairs & Strategy, Oncol, Sunnyvale, CA USA
关键词
MESSENGER-RNA; IN-SITU; IMMUNOHISTOCHEMISTRY; CARCINOMA; TAMOXIFEN; ASSAY;
D O I
10.1038/s41374-018-0064-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An on-demand, closed RT-qPCR, the GeneXpert (GX) system, has the potential to provide biomarker information in low-resourced settings and elsewhere. We used this system with a research use only version of the Breast Cancer STRAT4 cartridge that measures the mRNA expression levels of ERBB2, ESR1, PGR, and MKi67. Here we evaluated the impact of non-macrodissected (non m-d) versus macrodissected (m-d) samples using STRAT4 on formalin-fixed, paraffin-embedded (FFPE) core needle biopsies. Two cohorts were assessed: (1) 60 FFPE infiltrating ductal carcinoma (IDCA) cases and (2) 20 FFPE IDCA cases with ductal carcinoma in situ (DCIS) with a range of HER2 expression as determined by clinical immunohistochemistry and fluorescence in situ hybridization (IHC/FISH). We observed about half of the core needle biopsy area as invasive tumor in both IDCA (mean = 51.5%) and IDCA with DCIS (mean = 53.5%) cohorts, but also found the mRNA levels were independent of tumor area. We found excellent agreement of the mRNA transcript level between the paired samples, m-d versus non m-d, for ERBB2, ESR1, PGR, and MKi67 for both the IDCA and IDCA with DCIS cohorts. No significant difference (P > 0.99) was observed when we compared the mRNA transcript level between the paired samples m-d versus non m-d. In addition, we noted a significant concordance (P < 0.001) between RT-qPCR and IHC/FISH for HER2-positivity, ER-positivity, and PR-positivity, independent of specimen dissection. These data suggest that mRNA expression for ERBB2, ESR, and PGR is sufficiently low in surrounding tissue cells such that macrodissection is not required for assessment of key breast cancer mRNA markers and is independent of the amount of input tumor. This approach may be valuable in settings lacking pathology expertise or using specimen types, such as fine-needle aspirates, where it may be challenging to separate non-tumor from tumor tissue.
引用
收藏
页码:1076 / 1083
页数:8
相关论文
共 50 条
  • [31] Prognostic Significance of Single Progesterone Receptor Positivity A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
    Fan, Ying
    Ding, Xiaoyan
    Xu, Binghe
    Ma, Fei
    Yuan, Peng
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Luo, Yang
    MEDICINE, 2015, 94 (46) : e2066
  • [32] Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
    Arnedos, M.
    Nerurkar, A.
    Osin, P.
    A'Hern, R.
    Smith, I. E.
    Dowsett, M.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1948 - 1952
  • [33] Automated Cellular Imaging System III for Assessing HER2 Status in Breast Cancer Specimens Development of a Standardized Scoring Method That Correlates With FISH
    Minot, Douglas M.
    Kipp, Benjamin R.
    Root, Renee M.
    Meyer, Reid G.
    Reynolds, Carol A.
    Nassar, Aziza
    Henry, Michael R.
    Clayton, Amy C.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (01) : 133 - 138
  • [34] Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer
    Avci, Nilufer
    Deligonul, Adem
    Tolunay, Sahsine
    Cubukcu, Erdem
    Olmez, Omer Fatih
    Ulas, Arife
    Hartavi, Mustafa
    Kurt, Ender
    Evrensel, Turkkan
    JOURNAL OF BUON, 2015, 20 (01): : 45 - 49
  • [35] Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
    Chen, Xiaosong
    Yuan, Ying
    Gu, Zhaoxiang
    Shen, Kunwei
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 957 - 967
  • [36] Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
    Karolina Lindberg
    Luisa A Helguero
    Yoko Omoto
    Jan-Åke Gustafsson
    Lars-Arne Haldosén
    Breast Cancer Research, 13
  • [37] Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
    Parise, Carol A.
    Bauer, Katrina R.
    Brown, Monica M.
    Caggiano, Vincent
    BREAST JOURNAL, 2009, 15 (06) : 593 - 602
  • [38] Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
    Sperduto, Paul W.
    Mesko, Shane
    Li, Jing
    Cagney, Daniel
    Aizer, Ayal
    Lin, Nancy U.
    Nesbit, Eric
    Kruser, Tim J.
    Chan, Jason
    Braunstein, Steve
    Lee, Jessica
    Kirkpatrick, John P.
    Breen, Will
    Brown, Paul D.
    Shi, Diana
    Shih, Helen A.
    Soliman, Hany
    Sahgal, Arjun
    Shanley, Ryan
    Sperduto, William
    Lou, Emil
    Everett, Ashlyn
    Boggs, Drexell Hunter
    Masucci, Laura
    Roberge, David
    Remick, Jill
    Plichta, Kristin
    Buatti, John M.
    Jain, Supriya
    Gaspar, Laurie E.
    Wu, Cheng-Chia
    Wang, Tony J. C.
    Bryant, John
    Chuong, Michael
    Yu, James
    Chiang, Veronica
    Nakano, Toshimichi
    Aoyama, Hidefumi
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2020, 22 (09) : 1359 - 1367
  • [39] Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report
    Tisman, Glenn
    TUMORI, 2009, 95 (06) : 804 - 807
  • [40] Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older
    Kim, Min Hwan
    Kim, Gun Min
    Kim, Jee Hung
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Cho, Young Up
    Park, Byeong Woo
    Kim, Seung Il
    Sohn, Joohyuk
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (03) : 687 - 697